Alfacalcidol Tablet is an oral vitamin D analog indicated for vitamin D metabolism disorders, helping improve symptoms such as hypocalcemia, tetany, bone pain, and bone lesions in patients with chronic renal failure, hypoparathyroidism, or vitamin D-resistant rickets and osteomalacia. It is also indicated for the treatment of osteoporosis.
YS Life Science has developed Alfacalcidol Tablet as part of its finished dosage form portfolio, supported by in-house API capability. The product is commercialized in 0.5 mcg and 1 mcg strengths. In particular, the 1 mcg tablet is positioned as a differentiated product in the Korean market, supported by YS Life Science’s integrated API and finished dosage form development capability.
*Key highlights:
Oral tablet formulation of alfacalcidol
Indicated for vitamin D metabolism-related disorders and osteoporosis
0.5 mcg and 1 mcg commercialized
In-house API capability
First 1 mcg tablet in Korea
